Company: NDRA
Filing Date: 2025-10-17
Form Type: PRE 14A
Source: 0001654954-25-011931
Chunk: 60

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-17
Form: PRE 14A
Chunk 60
---
 basis, dividends or dividend equivalents with respect to the common stock or other securities covered by an award. The terms and conditions of a dividend equivalent right may be set forth in the award agreement. Dividend equivalents credited to a grantee may be paid currently or may be deemed to be reinvested in additional shares or other securities of the Company at a price per unit equal to the fair market value on the date that such dividend was paid to stockholders.

| 42 |

Historical Awards

Since its adoption, awards covering 711,855 shares of common stock have been granted under the 2016 Plan, whether or not currently outstanding, vested, or forfeited, including (i) awards covering 26,932 shares to Alexander Tokman, (ii) awards covering 96 shares to Francois Michelon, (iii) awards covering 93 shares to Michael Thornton, (iv) awards covering 13,461 shares to Richard Jacroux, (v) awards covering 7 shares to Irina Pestrikova, (vi) awards covering 40,556 shares to all current executive officers as a group, (vii) awards covering 16,152 shares to all current non-employee directors, and (viii) awards covering [●] shares to all employees, excluding current executive officers, as a group.

New Plan Benefits

No awards have been made under the 2016 Plan, and no awards have been granted that are contingent on the approval of the 2016 Plan. Future awards under the 2016 Plan would be made at the discretion of the Board or its delegate. Therefore, the benefits and amounts that will be received or allocated under the 2016 Plan in the future are not determinable at this time.

Equity Compensation Plan Table

The following table presents information on the Company’s equity compensation plans as of December 31, 2024. All outstanding awards relate to our common stock.

| Plan Category                                              |     | Number of Securities to Be Issued upon Exercise of Outstanding Options, Warrants and Rights(a) |        |     | Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights(b) |           |     | Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans (Excluding Securities Reflected in Column (a))(c) |          |
|:-----------------------------------------------------------|:----|:-----------------------------------------------------------------------------------------------|-------:|:----|:-------------------------------------------------------------------------------|----------:|:----|:-----------------------------------------------------------------------------------------------------------------------------------------------|---------:|
| Equity